Book reading complete · selected evidence checked · October 5, 2026
Original educational notes on the full reading (through The End) of Matthew Farrahi’s Peptides Made Simple: Usage, Dosing, Cycling & More. The book is the subject of review, not a medical authority. This is a concise critical synthesis, not a reproduction of the book. Scientific verification is selective: it is not a complete audit of every claim or every bibliography citation.
1. Know the level of evidence.
Cell experiments, animal studies, early human studies and controlled clinical trials answer different questions. A finding at one level does not carry over automatically to the next. Ask what was measured, in whom, for how long and against what comparison. Personal experience and confident rankings are not substitutes for those answers.
2. Mechanisms and biomarkers are not patient outcomes.
A plausible biological mechanism, or a change in a hormone, enzyme or laboratory marker, does not by itself show that people feel, function or live better. A long benefit list needs claim-by-claim evidence, and a short adverse-effect list does not show that risks have been studied.
3. Exact identity and context matter.
The exact molecule, formulation, route, population and endpoint all shape what a study can show. A full-length protein and a fragment of it are not interchangeable, and an unapproved analog is not the same thing as an approved medicine with a related name. One classification correction from this review: 5-amino-1MQ is described in the cited primary paper as a small-molecule NNMT inhibitor; its mouse findings are not evidence of human treatment effectiveness.
4. Combinations add uncertainty.
Evidence about a single ingredient does not establish the effects of a mixture. Combining substances adds unknowns about interactions, and a mechanistic “synergy” rationale does not establish clinical safety or benefit. Supplier documentation, product identity and published studies are separate things to evaluate.
5. Keep source limits visible.
The book’s author describes personal opinions and experience and states that he has no medical degree or equivalent professional accreditation. The book includes preferences, proposed regimens, combinations, practical material and commercial back matter. These notes do not reproduce or endorse any protocols, amounts, schedules, cycling, administration, reconstitution guidance, combinations, vendor endorsements or course offers.
6. Evidence-literacy examples from FDA staff reviews
The documents below are FDA staff briefing evaluations prepared for the Pharmacy Compounding Advisory Committee (July 2026) — FDA staff evaluations for an advisory committee, not final FDA approvals or regulatory decisions. Short summaries only — read the originals.
BPC-157
Staff identified limited human studies, but found no published studies for the proposed oral, subcutaneous, nasal or transdermal routes. Evidence was insufficient for the evaluated ulcerative-colitis use.
FDA staff briefing document (PDF)Semax
Evidence is route- and form-specific: staff note Semax is registered in Russia, could not find human pharmacokinetic studies by any route, noted studies often did not specify which form was used, and found insufficient evidence of effectiveness for the nominated stroke and transient ischemic attack (TIA) uses.
FDA staff briefing document (PDF)TB-500
Identity matters: staff describe TB-500 as a seven-amino-acid synthetic fragment, not full-length thymosin beta-4, and note an absence of human data on products containing it by any route.
FDA staff briefing document (PDF)Epitalon
Staff found insufficient evidence for insomnia and insufficient human safety information. Reported effects on telomerase, telomeres or melatonin do not establish clinical benefit. The review raises mechanistic cancer concerns, not proof that Epitalon causes cancer in people.
FDA staff briefing document (PDF)
Related context: compounded drugs are not FDA-approved, as FDA explains in Compounding and the FDA: Questions and Answers.
7. Concluding themes from the full reading
Original methodological critiques, not product claims.
Combination narratives are not combination trials.
Proposed combination rationales and the author’s bar-chart style rankings do not establish outcomes from controlled trials of those combinations. Some opinions in the book describe combinations the author says he has not personally tried.
Biomarkers and mechanisms are not proof of major outcomes.
Telomere, growth-hormone, mitochondrial or neuronal markers and mechanisms, on their own, cannot establish longer human life, treatment of brain injury, cancer prevention or the cure of an infection.
“Natural” is not safety evidence; topical is not injection.
Natural origin is not comparative safety evidence. Topical or cosmetic findings cannot establish the safety of injection or microneedling.
References must match the claim.
A cited study supports a claim only when it matches the exact molecule, route, population and measured outcome. The presence of a bibliography does not by itself validate every recommendation.
Labels, calculators and purity reports have limits.
Laboratory labels, calculators and purity reports do not make a material appropriate for human use, and they do not establish formulation stability, sterility or compatibility when materials are mixed.
8. Questions worth keeping.
- What is the original source?
- Is the finding from cells, animals or people?
- Is it the exact molecule, form and route being claimed?
- Was a patient outcome measured, or only a marker?
- What limitations or conflicts are disclosed?
- Has another group replicated it?
- What is still unknown?
Coverage
Reading complete as of October 5, 2026 (Kindle, through The End, last spread 488/489): all 18 chapters, including combination chapters 10–16, the practical chapter 17 and closing chapter 18, plus the bibliography and commercial back matter. Evidence checks were selective — the FDA staff evaluations above and the cited primary paper — and do not audit every claim or citation.
Sources
- NIH peptide glossary: genome.gov/genetics-glossary/Peptide
- Primary classification/preclinical paper: pmc.ncbi.nlm.nih.gov/articles/PMC5826726
- Book credited above as the subject of review, not clinical authority.